Future Roadmaps for Precision Medicine Applied to Diabetes: Rising to the Challenge of Heterogeneity

Overview

Journal J Diabetes Res

Publisher Wiley

Specialty Endocrinology

Date 2019 Jan 2

PMID 30599002

Citations 6

Authors

P Bowman

S E Flanagan

A T Hattersley

Affiliations

Soon will be listed here.

Abstract

Precision medicine, the concept that specific treatments can be targeted to groups of individuals with specific genetic, cellular, or molecular features, is a key aspect of modern healthcare, and its use is rapidly expanding. In diabetes, the application of precision medicine has been demonstrated in monogenic disease, where sulphonylureas are used to treat patients with neonatal diabetes due to mutations in ATP-dependent potassium (K) channel genes. However, diabetes is highly heterogeneous, both between and within polygenic and monogenic subtypes. Making the correct diagnosis and using the correct treatment from diagnosis can be challenging for clinicians, but it is crucial to prevent long-term morbidity and mortality. To facilitate precision medicine in diabetes, research is needed to develop a better understanding of disease heterogeneity and its impact on potential treatments for specific subtypes. Animal models have been used in diabetes research, but they are not translatable to humans in the majority of cases. Advances in molecular genetics and functional laboratory techniques and availability and sharing of large population data provide exciting opportunities for human studies. This review will map the key elements of future diabetes research in humans and its potential for clinical translation to promote precision medicine in all diabetes subtypes.

Citing Articles

Etiologies underlying subtypes of long-standing type 2 diabetes.

Bayoumi R, Farooqi M, Alawadi F, Hassanein M, Osama A, Mukhopadhyay D PLoS One. 2024; 19(5):e0304036.

PMID: 38805513 PMC: 11132508. DOI: 10.1371/journal.pone.0304036.

Pantazis L, Frechtel G, Cerrone G, Garcia R, Iglesias Molli A EJIFCC. 2023; 34(3):228-244.

PMID: 37868088 PMC: 10588079.

Clinical Characteristics of Inpatients With New-Onset Diabetes Mellitus in Eastern China: Based on Novel Clustering Analysis.

Song X, Lv Y, Huang N, Sun J, Yang T, Wang X Front Endocrinol (Lausanne). 2022; 13:927661.

PMID: 35966053 PMC: 9363570. DOI: 10.3389/fendo.2022.927661.

The clinical consequences of heterogeneity within and between different diabetes types.

Redondo M, Hagopian W, Oram R, Steck A, Vehik K, Weedon M Diabetologia. 2020; 63(10):2040-2048.

PMID: 32894314 PMC: 8498993. DOI: 10.1007/s00125-020-05211-7.

Challenges of Clustering Multimodal Clinical Data: Review of Applications in Asthma Subtyping.

Horne E, Tibble H, Sheikh A, Tsanas A JMIR Med Inform. 2020; 8(5):e16452.

PMID: 32463370 PMC: 7290450. DOI: 10.2196/16452.

References

Gale E, Gillespie K . Diabetes and gender. Diabetologia. 2001; 44(1):3-15. DOI: 10.1007/s001250051573. View

Mathews C, Langley S, Leiter E . New mouse model to study islet transplantation in insulin-dependent diabetes mellitus. Transplantation. 2002; 73(8):1333-6. DOI: 10.1097/00007890-200204270-00024. View

Bao M, Yang Y, Jun H, Yoon J . Molecular mechanisms for gender differences in susceptibility to T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol. 2002; 168(10):5369-75. DOI: 10.4049/jimmunol.168.10.5369. View

Yang Q, Yamagata K, Fukui K, Cao Y, Nammo T, Iwahashi H . Hepatocyte nuclear factor-1alpha modulates pancreatic beta-cell growth by regulating the expression of insulin-like growth factor-1 in INS-1 cells. Diabetes. 2002; 51(6):1785-92. DOI: 10.2337/diabetes.51.6.1785. View

Macmurray A, Moralejo D, Kwitek A, Rutledge E, Van Yserloo B, Gohlke P . Lymphopenia in the BB rat model of type 1 diabetes is due to a mutation in a novel immune-associated nucleotide (Ian)-related gene. Genome Res. 2002; 12(7):1029-39. PMC: 186618. DOI: 10.1101/gr.412702. View

Gloyn A, Weedon M, Owen K, Turner M, Knight B, Hitman G . Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes. 2003; 52(2):568-72. DOI: 10.2337/diabetes.52.2.568. View

Gale E, Bingley P, Emmett C, Collier T . European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004; 363(9413):925-31. DOI: 10.1016/S0140-6736(04)15786-3. View

Gloyn A, Pearson E, Antcliff J, Proks P, Bruining G, Slingerland A . Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004; 350(18):1838-49. DOI: 10.1056/NEJMoa032922. View

Sagen J, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H . Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes. 2004; 53(10):2713-8. DOI: 10.2337/diabetes.53.10.2713. View

10.

Vaxillaire M, Populaire C, Busiah K, Cave H, Gloyn A, Hattersley A . Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes. 2004; 53(10):2719-22. DOI: 10.2337/diabetes.53.10.2719. View

11.

Bingham C, Hattersley A . Renal cysts and diabetes syndrome resulting from mutations in hepatocyte nuclear factor-1beta. Nephrol Dial Transplant. 2004; 19(11):2703-8. DOI: 10.1093/ndt/gfh348. View

12.

Zung A, Glaser B, Nimri R, Zadik Z . Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab. 2004; 89(11):5504-7. DOI: 10.1210/jc.2004-1241. View

13.

Rees D, Alcolado J . Animal models of diabetes mellitus. Diabet Med. 2005; 22(4):359-70. DOI: 10.1111/j.1464-5491.2005.01499.x. View

14.

Klupa T, Edghill E, Nazim J, Sieradzki J, Ellard S, Hattersley A . The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the.... Diabetologia. 2005; 48(5):1029-31. DOI: 10.1007/s00125-005-1731-5. View

15.

Shoda L, Young D, Ramanujan S, Whiting C, Atkinson M, Bluestone J . A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity. 2005; 23(2):115-26. DOI: 10.1016/j.immuni.2005.08.002. View

16.

Colombo C, Delvecchio M, Zecchino C, Faienza M, Cavallo L, Barbetti F . Transient neonatal diabetes mellitus is associated with a recurrent (R201H) KCNJ11 (KIR6.2) mutation. Diabetologia. 2005; 48(11):2439-41. DOI: 10.1007/s00125-005-1958-1. View

17.

Feigerlova E, Pruhova S, Dittertova L, Lebl J, Pinterova D, Kolostova K . Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents. Eur J Pediatr. 2006; 165(7):446-52. DOI: 10.1007/s00431-006-0106-3. View

18.

Flanagan S, Edghill E, Gloyn A, Ellard S, Hattersley A . Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia. 2006; 49(6):1190-7. DOI: 10.1007/s00125-006-0246-z. View

19.

Peltonen L, Perola M, Naukkarinen J, Palotie A . Lessons from studying monogenic disease for common disease. Hum Mol Genet. 2006; 15 Spec No 1:R67-74. DOI: 10.1093/hmg/ddl060. View

20.

Gloyn A, Diatloff-Zito C, Edghill E, Bellanne-Chantelot C, Nivot S, Coutant R . KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features. Eur J Hum Genet. 2006; 14(7):824-30. DOI: 10.1038/sj.ejhg.5201629. View